Artelo Biosciences Updates on Progress and Financial Health

Artelo Biosciences Reports Key Business Updates

Artelo Biosciences, Inc., a clinical-stage pharmaceutical company committed to developing innovative treatments focused on lipid-signaling pathways, has provided a comprehensive business update along with its financial and operational results for the fiscal year ending December 31, 2024. With a mission directed towards people living with cancer, pain, and other conditions, Artelo is making transformative strides in its clinical programs.

Significant Business Highlights

Artelo continues to make progress in advancing its product pipeline, and it is noteworthy that various pivotal clinical milestones are approaching in 2025. Among the highlights:

• ART26.12: The Phase I study is on track for completion by the second quarter of 2025.
• ART27.13: The company anticipates initial data from the Phase 2 CAReS trial by the end of Q2 2025.
• ART12.11: Significant advancement has been made in preparations for human studies with this innovative oral solid dosage form expected in the second half of 2025.

Gregory D. Gorgas, President and CEO, expressed his enthusiasm regarding the rapid pace of enrollment in the Phase 1 study of ART26.12, aimed at addressing significant unmet medical needs. "The compound is the first selective FABP5 inhibitor under the firm's proprietary platform to enter human studies, with expected therapeutic potential across various applications related to lipid signaling," Gorgas stated.

Looking Ahead to 2025

In addition to ART26.12, Mr. Gorgas revealed optimism about receiving initial data from the Phase 2 CAReS study involving ART27.13. This compound aims to improve conditions related to cancer anorexia and weight loss, demonstrating a promising safety profile previously observed in the Phase 1 study.

Fiscal Year 2024 Financial Overview

As part of its year-end reporting, Artelo detailed its financial performance, outlining key metrics for the year ended December 31, 2024:

• Research and Development (R&D) Expenses: R&D expenses amounted to $6.0 million, a slight increase from $5.7 million in 2023.
• General and Administrative (G&A) Expenses: The G&A expenses were reported at $4.1 million for the year, slightly down from $4.2 million in 2023.
• Net Loss: Artelo recorded a net loss of $9.8 million, equivalent to $3.05 per basic and diluted common share. For the previous year, the net loss was $9.3 million, or $3.14 per share.
• Cash and Investments: The company reported cash and investments totaling $2.3 million as of December 31, 2024.

Innovative Therapeutics in Development

Artelo is developing several key therapeutic entities, including:

ART26.12

As the company’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12 aims to serve as a groundbreaking, non-opioid analgesic. The FDA has cleared it for first-in-human studies, with clinical trials targeted for chemotherapy-induced peripheral neuropathy.

ART27.13

This innovative compound serves as a once-daily oral agent, selectively activating cannabinoid receptors that could improve weight and appetite in cancer patients. Originally developed by a leading pharmaceutical company, ART27.13 aims to facilitate better quality of life measures for patients suffering from cancer-related issues.

ART12.11

Artelo's unique cocrystal formulation of cannabidiol (CBD) and tetramethylpyrazine (TMP) displays enhanced pharmacokinetics and efficacy, potentially paving the way for safer and more effective CBD pharmaceuticals well into the future.

About Artelo Biosciences

Artelo Biosciences is a company passionate about its work in developing therapies to address unmet medical needs across various disease conditions, including cancer, anxiety, and more. With a leadership team composed of experienced industry professionals, they emphasize advanced research, regulatory rigor, and a commitment to impactful therapeutics.

For more insights, interested individuals can reach out to Crescendo Communications, LLC, at 212-671-1020 or via email at ARTL@crescendo-ir.com.

Frequently Asked Questions

What is the primary focus of Artelo Biosciences?

Artelo focuses on the development of innovative therapies that modulate lipid-signaling pathways for treating various medical conditions.

When is the anticipated completion date for the Phase I study of ART26.12?

The Phase I study of ART26.12 is expected to conclude in the second quarter of 2025.

What were the R&D expenses for the fiscal year 2024?

Artelo reported R&D expenses of $6.0 million for the fiscal year ending December 31, 2024.

What is the significance of ART27.13?

ART27.13 is being evaluated as a potential treatment for cancer anorexia and weight loss, offering a new approach to improving patient appetite and body weight.

How can I find more information about Artelo Biosciences?

For further details, please visit the official Artelo Biosciences website at www.artelobio.com.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.